Fda states that veru should submit request for emergency use authorization (eua) based on positive efficacy and safety data from the phase 3 clinical study of sabizabulin in hospitalized covid-19 patients

-- fda agrees that no additional efficacy studies or safety data are required to support a request for eua -- -- a request for eua is planned for submission in calendar 2q 2022-- --company plans to meet with u.s. and ex-u.s. government officials to discuss advance purchase agreements -- --the company has a planned investor's conference call at 8:00 am et on may 12, 2022 and will discuss the outcome of the fda meeting and next steps --
VERU Ratings Summary
VERU Quant Ranking